Express News | The USA Biological Security Act was not included in the CR bill.

BreakingsDec 18 15:53

HBM HOLDINGS-B (02142.HK) has reached a development cooperation with Candid on the next-generation T cell connector.

On December 16, 2023, HBM HOLDINGS-B (02142.HK) announced that its wholly-owned subsidiary, Nona Bioscience (Suzhou) Co., Ltd. (Nona Bioscience), has reached a research collaboration and licensing agreement with Candid Therapeutics, Inc. (Candid) to develop the next-generation T cell connector. According to the terms of the agreement, Nona Bioscience is entitled to receive an upfront payment and potential milestone payments of up to 0.32 billion USD. Candid will be responsible for all subsequent development work on the product. Candid Therapeutics, Inc. is

Gelonghui FinanceDec 16 20:07

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 9 12:10

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 16:48

Buyback gathering on November 28th | tencent, aia insurance, etc. have all repurchased, with tencent spending 0.7 billion Hong Kong dollars.

According to the disclosure on November 29 by hkex, tencent bought back 1.75 million ordinary shares on November 28, involving 0.7 billion Hong Kong dollars, with a repurchase price ranging from 403.8 Hong Kong dollars to 397.6 Hong Kong dollars per share. Since the repurchase authorization resolution, the cumulative number of repurchased securities is 0.195 billion shares, accounting for 2.072% of the number of shares issued when the ordinary resolution was passed. aia bought back shares on 11

Futu NewsNov 29 09:10

Baheal Pharma-B (02142.HK) spent 0.071 million Hong Kong dollars to buy back 0.06 million shares on November 28th.

On November 28, Herbet Pharmaceuticals-B (02142.HK) announced that on November 28, 2024, it will spend 0.071 million Hong Kong dollars to repurchase 0.06 million shares, with a repurchase price of 1.18-1.19 Hong Kong dollars per share.

Gelonghui FinanceNov 28 18:49